News Releases

Astellas Named to FTSE4Good Sustainability Index for the Third Year

Tokyo, Dec. 9, 2014 – Astellas Pharma Inc. (TSE: 4503; Headquarters: Tokyo; President & CEO: Yoshihiko Hatanaka) announced that it has been selected for the third year to be included in the FTSE4Good Index, one of the world’s premier indexes for socially responsible investment.

Managed by FTSE (Financial Times Stock Exchange) Group, the FTSE4Good Index is used by investors around the world to assess best practices and social responsibility criteria to inform investment strategies. The FTSE Group applies its own criteria for selection from 2,400 companies in 23 countries. As of Sept. 30, 2014, 780 companies from around the world, including 176 Japanese companies, were selected as the constituents of this index. FTSE uses unique criteria which contain 14 themes relevant to environment, social and governance. FTSE, together with the Dow Jones Sustainability Index (DJSI), are the most recognized sustainability indexes worldwide. Astellas has been listed in the DJSI Asia Pacific for the fourth consecutive year.

Astellas is committed to striving toward sustainable enhancement of enterprise value while remaining acutely aware of our social responsibilities. This involves taking a broad view that considers business, society and humanity so the company can exist not merely as a market entity, but also as a valuable member of society. Astellas uses this approach as a cornerstone for all of its corporate activities.

About Astellas

Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at You can also follow us on Twitter at @AstellasUS.


For further information: Jenny Kite 224-205-5405
Stay Connected

Get only the email alerts you want.


Media Contacts


For media inquiries and reporter requests, please click here to fill out a request form.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.


Astellas on Twitter
Download Fact Sheet
Explore U.S. Products